Ownership history in Trexquant Investment LP Β· 28 quarters on record
This page tracks every 13F SEC filing in which Trexquant Investment LP reported a position in AMICUS THERAPEUTICS INC (FOLD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Trexquant Investment LP underperformed the S&P 500 by β52.2% annually on this FOLD position. Timing score: 52% (14/27 decisions correct). Average cost basis: $9.09. Maximum drawdown during holding period: β75.2%.
β Significantly underperformed the S&P 500 by 52.2% ann.
6 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
14 of 27 add/trim decisions correct
Best entry: $5.46 (2016 Q2) Β· Worst: $23.09 (2020 Q4)
πͺ Held through 3 major drawdowns (>20%). Diamond-hands conviction.
14 adds Β· 14 trims. Bought during 9 of 14 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.04% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size